151 related articles for article (PubMed ID: 36864544)
1. Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration-expedited programs.
Jenkins NB; Rucker JA; Klimchak AC; Sedita LE; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):472-479. PubMed ID: 36864544
[No Abstract] [Full Text] [Related]
2. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Panzer AD; Ingham M; Martin S; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
[No Abstract] [Full Text] [Related]
3. Specialty drug coverage varies between health plans' medical and pharmacy benefit policies.
Levine AA; Panzer AD; Kauf TL; O'Sullivan AK; Strand L; Chambers JD
J Manag Care Spec Pharm; 2023 Jun; 29(6):607-613. PubMed ID: 37276044
[No Abstract] [Full Text] [Related]
4. Variation in health plan coverage of ESAs for anemia due to chronic kidney disease.
Margaretos NM; Panzer AD; Lai RC; Sanon M; Michalopoulos E; Redmond AM; Moghadam R; Chambers JD
J Manag Care Spec Pharm; 2021 Sep; 27(9):1221-1229. PubMed ID: 34464213
[No Abstract] [Full Text] [Related]
5. US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies.
Rucker JA; Beinfeld MT; Enright DE; Germack HD; Panjabi S; Chakinala MM; Chambers JD
J Manag Care Spec Pharm; 2024 Jun; 30(6):541-548. PubMed ID: 38824632
[TBL] [Abstract][Full Text] [Related]
6. Patients' access to 2018 FDA-approved drugs 1 year post approval.
Panzer AD; Margaretos NM; Bridger N; Osani MC; Lai RC; Chambers JD
Am J Manag Care; 2022 Apr; 28(4):e153-e156. PubMed ID: 35420754
[TBL] [Abstract][Full Text] [Related]
7. Commercial coverage of specialty drugs, 2017-2021.
Rucker JA; Beinfeld MT; Jenkins NB; Enright DE; Henderson RR; Chambers JD
Health Aff Sch; 2023 Aug; 1(2):qxad030. PubMed ID: 38756241
[TBL] [Abstract][Full Text] [Related]
8. Use of prescriber requirements among US commercial health plans.
Lenahan K; Panzer AD; Gertler R; Chambers JD
J Manag Care Spec Pharm; 2021 Dec; 27(12):1757-1762. PubMed ID: 34818091
[No Abstract] [Full Text] [Related]
9. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?
Chambers JD; Margaretos NM; Enright DE; Wang R; Ye X
Pharmacoeconomics; 2022 Feb; 40(2):225-232. PubMed ID: 34697718
[TBL] [Abstract][Full Text] [Related]
10. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
Shaw DL; Dhruva SS; Ross JS
J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
[TBL] [Abstract][Full Text] [Related]
11. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
[No Abstract] [Full Text] [Related]
12. Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs.
Chambers JD; Wilkinson CL; Anderson JE; Chenoweth MD
J Manag Care Spec Pharm; 2016 Oct; 22(10):1176-81. PubMed ID: 27668566
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Patients' access to rare neuromuscular disease therapies varies across US private insurers.
Margaretos NM; Bawa K; Engmann NJ; Chambers JD
Orphanet J Rare Dis; 2022 Feb; 17(1):36. PubMed ID: 35123543
[TBL] [Abstract][Full Text] [Related]
15. Variation in access to hemophilia A treatments in the United States.
Margaretos NM; Patel AM; Panzer AD; Lai RC; Whiteley J; Chambers JD
J Med Econ; 2021; 24(1):1143-1148. PubMed ID: 34538215
[TBL] [Abstract][Full Text] [Related]
16. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.
Chambers JD; Pope EF; Wilkinson CL; Neumann PJ
J Manag Care Spec Pharm; 2018 Dec; 24(12):1240-1246. PubMed ID: 30479201
[TBL] [Abstract][Full Text] [Related]
17. Variation in US private health plans' coverage of orphan drugs.
Chambers JD; Panzer AD; Kim DD; Margaretos NM; Neumann PJ
Am J Manag Care; 2019 Oct; 25(10):508-512. PubMed ID: 31622066
[TBL] [Abstract][Full Text] [Related]
18. Coverage of New Drugs in Medicare Part D.
Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
[TBL] [Abstract][Full Text] [Related]
19. Varied use of step therapy among Medicare Advantage plans.
Jenkins NB; Nichols DE; Enright DE; Chambers JD
Am J Manag Care; 2023 Sep; 29(9):464-468. PubMed ID: 37729529
[TBL] [Abstract][Full Text] [Related]
20. Specialty Drug Coverage Varies Across Commercial Health Plans In The US.
Chambers JD; Kim DD; Pope EF; Graff JS; Wilkinson CL; Neumann PJ
Health Aff (Millwood); 2018 Jul; 37(7):1041-1047. PubMed ID: 29985695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
